Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder that is associated with abnormal accumulation of fat in the liver, which can lead to a wide variety of pathological liver defects and associated insulin resistance (IR), obesity, hypertension, dyslipidemia, diabetes, and cardiovascular disease. The molecular mechanisms that cause the initiation and progression of NAFLD are not fully understood. Increased lipolysis and de novo hepatic lipid synthesis lead to oxidative stress induced by reactive oxygen species and inflammation. Both these two entities could be interrelated and be an important mechanistic pathway, which can lead to tissue injury and hepatic cell death. Mechanisms for worsening of NAFLD include mitochondrial abnormalities, downregulation of glutathione (GSH), decreased activity of GSH-dependent antioxidants, accumulation of activated macrophages, hepatic inflammation, systemic inflammation, IR, and poorly controlled type 2 diabetes mellitus. Although no specific therapy has been approved for NAFLD, we review the latest medical therapeutics with emphasis on stem cell-based possibilities based on the presumed pathophysiology of NAFLD.
Get full access to this article
View all access options for this article.
References
1.
CotterTG, RinellaM. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology, 2020; 158(7):1851–1864.
2.
HalesCM, CarrollMD, FryarCD, et al.Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, 2020(360):1–8.
3.
YounesR, BugianesiE. A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. Nat Rev Gastroenterol Hepatol, 2019; 16(2):80–82.
4.
AnsteeQM, TargherG, DayCP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol, 2013; 10(6):330–344.
5.
AnguloP, KleinerDE, Dam-LarsenS, et al.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2015; 149(2):389.e10–397.e10.
6.
LewisJR, MohantySR. Nonalcoholic fatty liver disease: A review and update. Dig Dis Sci, 2010; 55(3):560–578.
7.
Rask-MadsenC, KingGL. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab, 2007; 3(1):46–56.
8.
García-CastroJ, TriguerosC, MadrenasJ, et al.Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med, 2008; 12(6b):2552–2565.
9.
IlkunO, BoudinaS. Cardiac dysfunction and oxidative stress in the metabolic syndrome: An update on antioxidant therapies. Curr Pharm Des, 2013; 19(27):4806–4817.
10.
SenS, DominguesCC, RouphaelC, et al.Genetic modification of human mesenchymal stem cells helps to reduce adiposity and improve glucose tolerance in an obese diabetic mouse model. Stem Cell Res Ther, 2015; 6:242.
11.
SchröderT, KucharczykD, BärF, et al.Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab, 2016; 5(4):283–295.
12.
PessayreD, FromentyB. NASH: A mitochondrial disease. J Hepatol, 2005; 42(6):928–940.
13.
CaldwellSH, SwerdlowRH, KhanEM, et al.Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol, 1999; 31(3):430–434.
14.
Pérez-CarrerasM, Del HoyoP, MartínMA, et al.Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003; 38(4):999–1007.
15.
ValerioA, CardileA, CozziV, et al.TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest, 2006; 116(10):2791–2798.
16.
DongiovanniP, LantiC, RisoP, et al.Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem, 2016; 29:1–11.
17.
SobermanRJ. The expanding network of redox signaling: New observations, complexities, and perspectives. J Clin Invest, 2003; 111(5):571–574.
18.
BalabanRS, NemotoS, FinkelT. Mitochondria, oxidants, and aging. Cell, 2005; 120(4):483–495.
19.
KeaneyJFJr., LarsonMG, VasanRS, et al.Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol, 2003; 23(3):434–439.
20.
FurukawaS, FujitaT, ShimabukuroM, et al.Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114(12):1752–1761.
21.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. US Department of Health and Human Services: Atlanta, GA; 2014.
22.
BrouwersB, HesselinkMK, SchrauwenP, et al.Effects of exercise training on intrahepatic lipid content in humans. Diabetologia, 2016; 59(10):2068–2079.
23.
JensenT, AbdelmalekMF, SullivanS, et al.Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol, 2018; 68(5):1063–1075.
24.
PattersonRE, LaughlinGA, LaCroixAZ, et al.Intermittent fasting and human metabolic health. J Acad Nutr Diet, 2015; 115(8):1203–1212.
25.
ChurchTS, KukJL, RossR, et al.Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology, 2006; 130(7):2023–2030.
26.
St GeorgeA, BaumanA, JohnstonA, et al.Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 2009; 50(1):68–76.
27.
TsunodaK, KitanoN, KaiY, et al.Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2021; 54(10):1330–1339.
28.
BacchiE, NegriC, TargherG, et al.Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology, 2013; 58(4):1287–1295.
29.
WibmerAG, BecherT, EljalbyM, et al.Brown adipose tissue is associated with healthier body fat distribution and metabolic benefits independent of regional adiposity. Cell Rep Med, 2021; 2(7):100332.
30.
SharmaS, MellsJE, FuPP, et al.GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One, 2011; 6(9):e25269.
31.
PetitJM, CercueilJP, LoffroyR, et al.Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD study. J Clin Endocrinol Metab, 2017; 102(2):407–415.
32.
HartmanML, SanyalAJ, LoombaR, et al.Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care, 2020; 43(6):1352–1355.
33.
NishimuraN, KitadeM, NoguchiR, et al.Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J Gastroenterol, 2016; 51(12):1141–1149.
34.
FakhryTK, MhaskarR, SchwitallaT, et al.Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis. Surg Obes Relat Dis, 2019; 15(3):502–511.
35.
Martínez-MontoroJI, KuchayMS, Balaguer-RománA, et al.Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev, 2022; 23(2):e13367.
36.
El BassatH, ZiadaDH, HasbyEA, et al.Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis. Arab J Gastroenterol, 2014; 15(1):6–11.
LiX, WangJ, GongX, et al.Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. Nucleic Acids Res, 2020; 48(15):8255–8268.
39.
LiuY, LiL, WuX, et al.MSC-AS1 induced cell growth and inflammatory mediators secretion through sponging miR-142-5p/DDX5 in gastric carcinoma. Aging (Albany NY), 2021; 13(7):10387–10395.
40.
XianP, HeiY, WangR, et al.Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. Theranostics, 2019; 9(20):5956–5975.
41.
HackelA, AksamitA, BruderekK, et al.TNF-α and IL-1β sensitize human MSC for IFN-γ signaling and enhance neutrophil recruitment. Eur J Immunol, 2021; 51(2):319–330.
42.
AlvesVBF, de SousaBC, FonsecaMTC, et al.A single administration of human adipose tissue-derived mesenchymal stromal cells (MSC) induces durable and sustained long-term regulation of inflammatory response in experimental colitis. Clin Exp Immunol, 2019; 196(2):139–154.
43.
WangC, FeiY, XuC, et al.Bone marrow mesenchymal stem cells ameliorate neurological deficits and blood-brain barrier dysfunction after intracerebral hemorrhage in spontaneously hypertensive rats. Int J Clin Exp Pathol, 2015; 8(5):4715–4724.
44.
ChenM, LiX, ZhangX, et al.The inhibitory effect of mesenchymal stem cell on blood-brain barrier disruption following intracerebral hemorrhage in rats: Contribution of TSG-6. J Neuroinflammation, 2015; 12:61.
45.
DulakJ, SzadeK, SzadeA, et al.Adult stem cells: Hopes and hypes of regenerative medicine. Acta Biochim Pol, 2015; 62(3):329–337.
46.
SeyfriedD, DingJ, HanY, et al.Effects of intravenous administration of human bone marrow stromal cells after intracerebral hemorrhage in rats. J Neurosurg, 2006; 104(2):313–318.
47.
SeyfriedDM, HanY, YangD, et al.Mannitol enhances delivery of marrow stromal cells to the brain after experimental intracerebral hemorrhage. Brain Res, 2008; 1224:12–19.
48.
OteroL, BonillaC, AguayoC, et al.Intralesional administration of allogeneic bone marrow stromal cells reduces functional deficits after intracerebral hemorrhage. Histol Histopathol, 2010; 25(4):453–461.
49.
SeyfriedDM, HanY, YangD, et al.Localization of bone marrow stromal cells to the injury site after intracerebral hemorrhage in rats. J Neurosurg, 2010; 112(2):329–335.
50.
LiangH, YinY, LinT, et al.Transplantation of bone marrow stromal cells enhances nerve regeneration of the corticospinal tract and improves recovery of neurological functions in a collagenase-induced rat model of intracerebral hemorrhage. Mol Cells, 2013; 36(1):17–24.
51.
DominguesCC, KunduN, KropotovaY, et al.Antioxidant-upregulated mesenchymal stem cells reduce inflammation and improve fatty liver disease in diet-induced obesity. Stem Cell Res Ther, 2019; 10(1):280.
52.
PoherAL, Veyrat-DurebexC, AltirribaJ, et al.Ectopic UCP1 overexpression in white adipose tissue improves insulin sensitivity in Lou/C rats, a model of obesity resistance. Diabetes, 2015; 64(11):3700–3712.
53.
XieZ, HaoH, TongC, et al.Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells, 2016; 34(3):627–639.
54.
DominguesCC, KunduN, DoreFJ, et al.Genetic Modification of Stem Cells in Diabetes and Obesity. In: Genetic Engineering—An Insight into the Strategies and Applications. (Jamal F. ed.) London: IntechOpen; 2016:75–84.
55.
SenS, StrappePM, O'BrienT. Gene transfer in endothelial dysfunction and hypertension. Methods Mol Med, 2005; 108:299–314.
56.
MahabadiAA, MassaroJM, RositoGA, et al.Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: The Framingham Heart Study. Eur Heart J, 2009; 30(7):850–856.
57.
HeQ, WangL, ZhaoR, et al.Mesenchymal stem cell-derived exosomes exert ameliorative effects in type 2 diabetes by improving hepatic glucose and lipid metabolism via enhancing autophagy. Stem Cell Res Ther, 2020; 11(1):223.
58.
DingJ, WangJ, ChenJ. Exosomes as therapeutic vehicles in liver diseases. Ann Transl Med, 2021; 9(8):735.
59.
IshidaK, SekiA, KawaguchiK, et al.Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. Stem Cell Res, 2021; 54:102425.
60.
MahmoudiA, ButlerAE, JamialahmadiT, et al.The role of exosomal miRNA in nonalcoholic fatty liver disease. J Cell Physiol, 2022; 237(4):2078–2094.
NakaoY, AmrollahiP, ParthasarathyG, et al.Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine, 2021; 36:102430.
63.
FergusonD, FinckBN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol, 2021; 17(8):484–495.
64.
MantovaniA, PetraccaG, BeatriceG, et al.Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials. Metabolites, 2021; 11(2):73.
65.
LuoQ, WeiR, CaiY, et al.Efficacy of off-label therapy for non-alcoholic fatty liver disease in improving non-invasive and invasive biomarkers: A systematic review and network meta-analysis of randomized controlled trials. Front Med (Lausanne), 2022; 9:793203.
66.
ShibukiK, ShimadaS, AoyamaT. Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin. Diabetes Metab Syndr, 2022; 16(4):102474.
67.
NicolucciA, MaffeisC. The adolescent with obesity: What perspectives for treatment?. Ital J Pediatr, 2022; 48(1):9.
68.
ZhongP, ZengH, HuangM, et al.Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: A meta-analysis. Endocrine, 2022; 75(3):718–724.
69.
KadowakiT, IsendahlJ, KhalidU, et al.Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol, 2022; 10(3):193–206.
70.
HinkeSA, MartensGA, CaiY, et al.Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer. Br J Pharmacol, 2007; 150(8):1031–1043.
71.
LazaridisN, TsochatzisE. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol, 2017; 11(4):357–369.
72.
PromratK, LutchmanG, UwaifoGI, et al.A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004; 39(1):188–196.
73.
RisérusU, SprecherD, JohnsonT, et al.Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 2008; 57(2):332–339.
PerumpailBJ, LiAA, JohnN, et al.The role of vitamin E in the treatment of NAFLD. Diseases, 2018; 6(4):86.
76.
PodszunMC, AlawadAS, LingalaS, et al.Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biol, 2020; 37:101710.
77.
JiHF, SunY, ShenL. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: Results from a meta-analysis. Nutrition, 2014; 30(9):986–991.
78.
LoguercioC, AndreoneP, BriscC, et al.Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic Biol Med, 2012; 52(9):1658–1665.
79.
HajighasemA, FarzanegiP, MazaheriZ. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. Arch Physiol Biochem, 2019; 125(2):142–149.
80.
SmithRA, PorteousCM, GaneAM, et al.Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A, 2003; 100(9):5407–5412.
81.
Asin-CayuelaJ, ManasAR, JamesAM, et al.Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett, 2004; 571(1–3):9–16.
82.
RokitskayaTI, KlishinSS, SeverinaII, et al.Kinetic analysis of permeation of mitochondria-targeted antioxidants across bilayer lipid membranes. J Membr Biol, 2008; 224(1–3):9–19.
83.
StaelsB, RubenstrunkA, NoelB, et al.Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2013; 58(6):1941–1952.
84.
Clinical Study. Safety and efficacy of selonsertib in adults with nonalcoholic steatohepatitis (NASH) and bridging (F3) fibrosis (STELLAR-3). ClinicalTrialsgov Identifier: NCT03053050. 2020.
85.
Ratziu LdGV, SafadiR, PoordadF, et al.One-year results of the global phase 2b randomized placebocontrolled ARREST trial of aramchol, a stearoyl CoA desaturase modulator in NASH patients. The Liver Meeting: American Association for the Study of Liver Diseases (AASLD): San Francisco, CA; 2018.
86.
SenS. Adult stem cells: Beyond regenerative tool, more as a bio-marker in obesity and diabetes. Diabetes Metab J, 2019; 43(6):744–751.
